Biogen (BIIB) Goldman Sachs 45th Annual Global Healthcare Conference summary

Strategic transformation and organizational focus

• Underwent significant re-engineering, shifting from survival to stabilization and now aiming for growth, with a new leadership team and board composition focused on long-term shareholder returns.

• Emphasized financial discipline and capital allocation, with the Fit for Growth initiative driving margin improvements and operational efficiency.

• Business development remains a priority, with recent acquisitions and ongoing efforts to expand the pipeline and product portfolio.

LEQEMBI launch progress and market dynamics

• LEQEMBI's launch has moved from a staged approach to expansion, with increasing numbers of HCPs and sites prescribing and ordering the drug.

• Major IDNs are now opening multiple child accounts, allowing broader patient access and more neurologists to prescribe.

• Expansion of the neurology sales force by 30% and a targeted DTC campaign are expected to accelerate adoption.

• The entry of a competitor is seen as positive for market development, with confidence in LEQEMBI's benefit-risk profile and upcoming long-term data readouts.

• Key launch metrics focus on the number of HCPs and sites coming online, with smaller practices' share of prescribing expected to shift toward IDNs over time.

Regulatory and product development updates

• IV maintenance filing for LEQEMBI has a PDUFA date of January 25 next year; subcutaneous maintenance filing expected to complete in Q3, with further optimization ongoing for induction dosing.

• Subcutaneous formulation is not expected to delay market progress, and multiple options are anticipated to enhance patient and physician choice.

• Medicare Part D redesign and IRA implications are being monitored, with a 13-year window before negotiation eligibility for biologics.